Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Yuchen LiQingkun SongBryan W DayPublished in: Acta neuropathologica communications (2019)
Sonidegib and vismodegib were well tolerated and demonstrated anti-tumour activity in SHH-driven paediatric and adult MB by effectively inhibiting Hh signalling. These results support the ongoing clinical trials using SMO inhibitors in combination with conventional chemotherapies for the treatment of relapsed MBSHH.
Keyphrases
- clinical trial
- phase ii
- basal cell carcinoma
- intensive care unit
- emergency department
- end stage renal disease
- acute lymphoblastic leukemia
- ejection fraction
- acute myeloid leukemia
- randomized controlled trial
- phase iii
- signaling pathway
- peritoneal dialysis
- diffuse large b cell lymphoma
- double blind
- smoking cessation
- childhood cancer